A Highly Therapy-Resistant Case of B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma Showing Strong BCL2 Staining, Otherwise Indistinguishable from Burkitt Lymphoma

この論文にアクセスする

この論文をさがす

著者

    • KURITA Naoki
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • NISHIKII Hidekazu
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • NAKAMOTO Rie
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • KONDO Yuzuru
    • Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • OKOSHI Yasushi
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • SUZUKAWA Kazumi
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • HASEGAWA Yuichi
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • YOKOYAMA Yasuhisa
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • NOGUCHI Masayuki
    • Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
    • CHIBA Shigeru
    • Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba

抄録

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (iDLBCL/BL) is a newly categorized lymphoma in the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues v4. This lymphoma has characteristics of both DLBCL and BL, morphologically and genetically. We report a case with therapy-resistant iDLBCL/BL, which used to be categorized as BL in the WHO Classification v3. This case showed strong BCL2 staining, otherwise exhibiting features of BL. The case was treated with intensive chemotherapy containing high-dose methotrexate, cyclophosphamide, and cytarabine. However, soon after the chemotherapy, the lymphoma relapsed in the central nervous system and was resistant to whole-brain radiation therapy and allogeneic stem cell transplantation. The patient died 37 days after the transplantation. The clinical course was different from that of typical BL in terms of resistance to intensive chemotherapy, in agreement with the characteristics of iDLBCL/BL. [<I>J Clin Exp Hematopathol 51(1) : 37-42, 2011</I>]

収録刊行物

  • Journal of clinical and experimental hematopathology

    Journal of clinical and experimental hematopathology 51(1), 37-42, 2011-05-01

    日本リンパ網内系学会

参考文献:  16件中 1-16件 を表示

各種コード

  • NII論文ID(NAID)
    10028239056
  • NII書誌ID(NCID)
    AA11556796
  • 本文言語コード
    ENG
  • 資料種別
    NOT
  • ISSN
    13464280
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ